Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) – Investment analysts at Cantor Fitzgerald lifted their FY2023 EPS estimates for Corvus Pharmaceuticals in a research note issued on Wednesday, March 29th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings of ($0.48) per share for the year, up from their previous forecast […]
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 200,200 shares, a growth of 16.9% from the February 28th total of 171,200 shares. Based on an average daily volume of 96,600 shares, the […]
Mizuho restated their neutral rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research report sent to investors on Thursday, Benzinga reports. The firm currently has a $3.50 target price on the stock. Separately, StockNews.com began coverage on Corvus Pharmaceuticals in a research report on Sunday, March 26th. They issued a sell […]
StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a report published on Sunday. The firm issued a sell rating on the stock. Corvus Pharmaceuticals Stock Up 11.3 % Shares of Corvus Pharmaceuticals stock opened at $0.72 on Friday. The company has a market capitalization of $33.59 million, a price-to-earnings ratio […]